SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

SPRB is trending due to a significant surge following FDA's breakthrough therapy designation, driving community discussion around a potential short squeeze and massive gains. The stock's low float is amplifying the volatility, with some speculating about potential buyout offers and comparing it to previous high-flying stocks. Traders are actively discussing price targets and exit strategies amid multiple trading halts.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending due to a major partnership with OpenAI, involving significant GPU deployments and a potential equity stake, leading to a surge in stock price. The community is discussing the implications of this deal for AMD's competitive position against Nvidia and the overall AI landscape. Some are speculating on future price targets and potential analyst upgrades following this news.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals ($CRML) is trending due to a volatile mix of speculation and conflicting reports regarding potential U.S. government investment in its Greenland rare earth project; community members are debating the legitimacy of news reports, with some believing it to be a coordinated short attack, while others remain optimistic about the company's long-term potential given the recent private funding news. The stock's price swings and trading halts reflect the uncertainty surrounding the deal and its implications for the critical minerals sector.

Society Pass, Inc. engages in the operation and acquisition of fintech and e-commerce platforms and mobile applications. It operates through the following segments: Online Food and Beverage (F&B) and Groceries Deliveries, Digital Marketing, Online Ticketing and Reservation, e-Commerce, Telecommunication Reseller, and Merchant Point of Sale (POS). The Online F&B and Groceries Deliveries segment includes the operation of Handycart, Mangan, and Pushkart brands. The Digital Marketing segment involves the engagement with creators and management of platforms. The Online Ticketing and Reservation segment focuses on the sale of domestic and overseas air ticket and global hotel reservations. The e-Commerce segment refers to the operation of an online lifestyle platform under the brand name Leflair. The Telecommunication Reseller segment consists of sales of local mobile phone plans and global internet data provider plans. The Merchant POS segment covers the sale of hardware and software. The company was founded by Luan Thuc Nguyen on June 22, 2018 and is headquartered in Carson City, NV.

Society Pass Inc

Society Pass Inc is trending as the community discusses its potential for a short squeeze, citing its low float and high volume. Some traders point to a recent analyst price target raise and are speculating about future IPOs related to the company. Others urge caution, mentioning past dilutions and the need for further catalysts.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid speculation of a potential partnership with Tesla, fueled by a teaser video featuring both companies. The community is buzzing with excitement, discussing potential price targets and the possibility of a short squeeze. With high trading volume and upcoming announcements, investors are closely watching for confirmation of the collaboration and its impact on the eVTOL market.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI CRYPTO is gaining attention, with community members highlighting the project's team and a potential CMC listing. Discussions also revolve around the "WAGMI ethos" being embraced by other communities, and the token's potential within the meme coin space on the SOL network. The community emphasizes the strong holder base and growing visibility across DeFi and social platforms.

HIVE Digital Technologies Ltd. engages in building a bridge between the digital currency and blockchain sector and traditional capital markets. It operates data centers for computing and mining cryptocurrencies, including Bitcoin and other coins. The firm owns and operates green energy-powered data center facilities in Canada, Sweden, and Iceland. Its project includes Iceland Cryptocurrency Mining. HIVE Digital Technologies was founded on June 24, 1987 and is headquartered in San Antonio, TX.

HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd

HIVE Digital Technologies is trending as community members discuss its potential for continued growth, citing factors like Bitcoin mining efficiency, diversification into AI, and institutional backing, including BlackRock's increased stake; the stock is showing high relative strength as it scales faster than ever with green energy.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending as the community discusses a potential short squeeze, with some highlighting high short interest and FTDs. Bullish sentiment is fueled by the possibility of accepting Bitcoin for home purchases, and some traders are pointing to technical indicators suggesting a breakout. The stock's recent price action and high trading volume are contributing to the increased attention.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as it makes new all-time highs, fueling excitement and bullish sentiment within the community. Discussions revolve around potential price targets, the impact of institutional investment via ETFs, and whether a supply shock could drive prices even higher. Some traders are looking for pullbacks to buy, while others speculate about an imminent surge to even higher levels.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as part of a broader surge in quantum computing stocks, with community members debating whether the sector is experiencing a bubble. Despite some skepticism about valuations and revenue, the stock has seen significant momentum, attracting both bulls anticipating further gains and bears betting on a correction or offering.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk

Zacks Value Trader weighs whether big pharma names like Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk are genuine bargains or value traps.

Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Can Novo Nordisk's Restructuring Program Drive its Return to Growth?

NVO is cutting 9,000 jobs, targeting DKK 8 billion in savings, and shifting focus to obesity and diabetes R&D to regain growth momentum.

After a rough few quarters for Novo Nordisk, investors are pinning hopes on an experimental Alzheimer’s pill to turn the tide.The Danish drugmaker is set to release late-stage Alzheimer’s trial results for a pill form of semaglutide — the key ingredient in Ozempic and Wegovy — by the year-end, according to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-01/novo-nordisk-investors-eye-alzheimer-s-trial-for-glimmer-of-hope">report</a>. The drug candidate is being evaluated in patients with mild Alzheimer’s disease.Analysts say the outcome could swing the stock sharply, with Morgan Stanley projecting a gain of up to 15% or a drop of up to 10%, depending on the results, although it assigns just a 25% chance of success.Novo shares have fallen 22% since July, marking the fourth quarter in five that they have witnessed a drop of over 20%, as the company faces profit downgrades, a CEO change, and intensifying competition from Eli Lilly and lower-cost GLP-1 rivals. Earlier this week, Morgan Stanley downgraded the stock to ‘Underweight,” citing weak visibility and growing risks.Still, Goldman Sachs and other analysts say a positive Alzheimer’s readout could be transformative, potentially expanding Novo’s reach beyond diabetes and obesity. Alzheimer’s remains a notoriously challenging field, as most treatments have failed. However, retrospective data hinting that GLP-1 drugs may offer cognitive protection has kept optimism alive.Novo’s two trials include over 3,500 participants and are the largest of their kind. If the results are positive, it would represent a huge surprise, said Sebastien Malafosse of Edmond de Rothschild Asset Management.On Stocktwits, retail sentiment for Novo Nordisk was ‘extremely bullish’ amid ‘high’ message volume.One user said they increased their Novo Nordisk position from 4,500 to 9,500 shares overnight and booked profits on part of the trade, calling it a “successful knife catch.”<stembedurl>https://stocktwits.com/FallingKnifeVictim/message/630562164</stembedurl>Another user remarked that Novo Nordisk had become a “scalper’s paradise,” often bouncing between losses at open and recovery by close.&nbsp;They suggested that some investors might be pressuring the company to adopt a more U.S.-focused strategy, similar to Pfizer’s recent move to join TrumpRx’s direct-to-consumer model, adding that such a shift could quickly restore market confidence.<stembedurl>https://stocktwits.com/Jippmeister/message/630564729</stembedurl><a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s U.S.-listed stock</a> has declined 34.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk Retail Traders Stay Bullish Despite Brutal 2025 — Analysts Flag A Key Catalyst That Can Turn Things Around  

Investors are betting that positive late-stage trial results for Novo Nordisk’s experimental Alzheimer’s pill could mark a major turnaround for the struggling drugmaker after months of steep losses and rising competition.

Equity

Can NVO Maintain Obesity Leadership With Next-Generation Candidates?

Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.

Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

LifeMD Inc. (LFMD) announced on Tuesday that it has partnered with Novo Nordisk AS (NVO) to offer Ozempic through an integration with NovoCare Pharmacy to eligible patients.According to the company’s announcement, eligible self-pay and uninsured patients, as well as insured patients whose plans do not cover GLP-1 therapies, now have direct access to all FDA-approved dose strengths of Ozempic within LifeMD’s end-to-end virtual care platform for $499 a month.<a href="https://stocktwits.com/symbol/LFMD">LifeMD’s shares</a> were up nearly 3% in Tuesday’s opening trade, while&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk's shares</a> were down 3%. Retail sentiment on Stocktwits around LifeMD trended in the ‘neutral’ territory, while users felt ‘extremely bullish’ about Novo Nordisk.LifeMD’s addition of Ozempic adds to the company’s existing offerings of GLP-1 therapies approved by the U.S. Food and Drug Administration (FDA), which include Novo&nbsp; Nordisk’s Wegovy.“Our expanded collaboration with Novo Nordisk further advances LifeMD’s mission to make high-quality, branded medications more affordable and accessible for millions of Americans,” said Justin Schreiber, Chairman and CEO of LifeMD.Ozempic currently has the broadest range of FDA-approved indications for adults with type 2 diabetes. Novo Nordisk’s expanded partnership with LifeMD comes amid concerns of the Ozempic-maker’s growth prospects in the U.S. in the weight loss prescription segment, said analysts at Morgan Stanley in a note on Monday, according to TheFly.The firm downgraded Novo Nordisk to ‘Underweight’ from ‘Equal Weight’ and lowered the price target to $47 from $59, implying a potential downside of nearly 13% from current levels. Morgan Stanley stated that Novo Nordisk lacks catalysts and that the stock carries downside risks over the next six months.<a href="https://stocktwits.com/symbol/LFMD">LFMD stock</a> is up 30% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 35%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nuscale-power-stock-gets-a-downgrade-by-bof-a-on-valuation-concerns/chDD4Z6R3BV">NuScale Power Stock Gets A Downgrade At BofA On Valuation Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A man holds an Ozempic brand slimming syringe in his hand

LifeMD Offers Novo Nordisk’s Ozempic For $499 A Month To Eligible Patients

Eligible self-pay and uninsured patients, as well as insured patients whose plans do not cover GLP-1 therapies, will have access to Ozempic through LifeMD’s platform for $499 a month.

Novo Nordisk A/S (NVO) shares slid 3% in the early premarket session on Monday as the Ozempic and Wegovy weight-loss drugmaker snagged a&nbsp;bearish recommendation from a Wall Street firm.&nbsp;Morgan Stanley analyst downgraded&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk stock</a> to ‘Underweight’ from ‘Equal Weight’ and also reduced the price target for the stock to $47 from $59, the excerpts of the note published by The Fly showed. Morgan Stanley’s updated price target implies a nearly 13% downside from the stock’s Friday close.The stock was among the top five trending equity tickers on Stocktwits early Monday. Retail sentiment toward the stock, however, remained ‘extremely bullish’ (76/100), and the message volume on the stream was ‘high.’<figure class="image"><img style="aspect-ratio:619/53;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_5_23_05_AM_png_5def6a683f.webp" alt="Screenshot 2025-09-29 at 5.23.05 AM.png" width="619" height="53"><figcaption>NVO sentiment and message volume as of 5:20 a.m. ET, Sept. 29 | source: Stocktwits</figcaption></figure>Morgan Stanley attributed its negative thesis on the Danish company to its view that the weight loss prescription growth in the U.S. would slow down amid competitive pressures. According to the firm, this would drive downside revisions to the 2026 and 2027 consensus estimates for Novo Nordisk.&nbsp;Analysts at the firm said the lack of momentum in U.S. prescriptions for Wegovy, Ozempic and Rybelsus makes it cautious on the company's short-term growth profile. Additionally, the analyst noted that the lack of catalysts exacerbates the downside risk profile over the next six months.A New York Times report stated last week that the company was cutting jobs following the profit warning it issued in late July.&nbsp;Novo Nordisk stock has lost over 34% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-analyst-says-i-phone-s-worst-period-in-china-has-passed/chDMvs4R378">Apple Analyst Says ‘iPhone’s Worst Period In China Has Passed’ — The Xiaomi Data That Adds Strength To Bull Case For Cupertino</a>

Why Wegovy Maker Novo Nordisk’s Stock Is Sliding 3% Premarket Today

Morgan Stanley attributed its negative thesis on the Danish company to its view that the weight loss prescription growth in the U.S. would slow down amid competitive pressures.

U.S. President Donald Trump said on Thursday that the United States will impose a 100% tariff on branded and patented pharmaceutical products starting Oct. 1 unless manufacturers are actively building plants in the country.&nbsp;As part of a series of late-night posts on Truth Social on Thursday,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/115267512131958759">Trump said</a> the exemption will apply only to firms that have “broken ground” or are “under construction.” “There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”&nbsp;The announcement intensifies the administration’s push to shift drug manufacturing to the U.S. Last month, Trump said the U.S. would begin with a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-plans-gradual-tariff-hike-on-imported-pharma-to-250-over-18-months-to-boost-us-production/chr1KgrRd2x">“small tariff”</a> on imported drugs before raising duties to 150% within 18 months and ultimately to 250%.&nbsp;Pharmaceuticals had previously been exempt from Trump’s reciprocal tariff program; however, the new duties will apply to prescription drugs, biologics, specialty medicines, and over-the-counter products, except for generic drugs, which remain excluded.Major drugmakers have responded unevenly.&nbsp;<a href="https://stocktwits.com/symbol/LLY">Eli Lilly</a> has committed more than $50 billion since 2020 to U.S. expansion, including $27 billion for four new “mega sites.” The company supports maintaining the U.S. as the “world’s leading destination for biopharmaceutical research and manufacturing” and agrees with the administration’s goal of more fairly sharing drug costs across developed countries, even as it warns that broad tariffs could raise costs and limit access.Lilly’s stream on Stocktwits gained traction late Thursday after Trump’s announcement, with sentiment tilting ‘bullish’ as retail traders bet that the company would benefit from the latest federal policy. “$LLY did great with plant announcement in houston this week. They wont have tariffs,”&nbsp;<a href="https://stocktwits.com/Gorohanada/message/630073275">said</a> one user.Several users noted that Novo Nordisk, Regeneron and Thermo Fisher also have U.S. sites that could qualify. Some argued investors misunderstand Novo’s footprint, contributing to its recent weakness despite likely exemptions.<stembedurl>https://stocktwits.com/3rdtimeretired/message/630071784</stembedurl><stembedurl>https://stocktwits.com/Bullish_Trader555/message/630067344</stembedurl><stembedurl>https://stocktwits.com/oldmanrizzer/message/630072277</stembedurl>AstraZeneca and Roche each announced plans this summer to invest $50 billion in new or expanded facilities across multiple states. Merck has invested more than $12 billion in U.S. manufacturing since 2017 and plans to invest an additional $9 billion by 2028, while Biogen has pledged $2 billion to upgrade its North Carolina plants.Others have taken a more cautious stance. Pfizer stated in March that it could shift overseas production to existing U.S. sites if necessary, but has not committed to new investment, whereas Novo Nordisk has yet to announce major U.S. projects.&nbsp;Trump’s Thursday night post followed the launch of fresh national security probes into imports of robotics, industrial machinery, and medical devices. The Commerce Department said on Wednesday that it launched investigations on Sept. 2 to determine if these imports could pose a risk to U.S. national security.&nbsp;On Stocktwits, retail sentiment for the SPDR S&amp;P Biotech ETF (XBI) was ‘bearish’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/XBI">XBI</a> has risen 6.5%. So far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025. (Photo by Andrew Harnik/Getty Images)

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America

Generic drugs remain exempt, while duties will apply to prescription, biologic, specialty and over-the-counter medicines.

Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?

VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVO News

NVO Novo Nordisk A/S